What 2026 Can Look Like for Your Patients: A 12-Month View of Muscle Health, Mobility, and Longevity with MYOS®

As veterinary medicine continues to place greater emphasis on preventive care and longevity, skeletal muscle health has emerged as a critical—but often under-addressed—component of long-term patient outcomes. Loss of muscle mass is not limited to geriatric patients; it begins earlier than many clinicians expect and accelerates with inactivity, chronic disease, recovery from injury or surgery, and age-related metabolic changes.

By incorporating MYOS® products containing Fortetropin® into year-long patient care plans, veterinarians can proactively support muscle preservation and function in both canine and feline patients. Below is a clinical look at what the first year on MYOS can look like—and how consistent muscle support can positively influence mobility, resilience, and quality of life throughout 2026 and beyond.

Months 0–3: Establishing the Foundation for Muscle Health

The first three months represent a critical period of intervention, particularly for patients already experiencing early muscle loss, reduced activity, or subclinical sarcopenia.

What veterinarians may observe:

• Stabilization of lean muscle mass in patients previously trending downward
• Improved willingness to move, rise, or engage in light activity
• Improved tolerance of physical rehabilitation or exercise programs
• Early improvements in muscle condition score (MCS), even when body weight remains unchanged

At this stage, MYOS works at the cellular level by supporting muscle protein synthesis through Fortetropin, a bioactive compound shown to stimulate muscle growth independent of exercise. This is particularly valuable for senior patients, cats with chronic disease, and dogs recovering from periods of disuse where exercise alone may be insufficient.

Clinical takeaway:
The first 90 days are about stopping muscle loss and setting the stage for recovery and preservation—especially in patients where traditional nutrition and activity have fallen short.

 

 

Months 3–6: Measurable Gains in Strength and Mobility

Between months three and six, many patients begin to demonstrate more visible and functional improvements. With continued daily supplementation, muscle tissue is better supported during normal activity and rehabilitation.

What veterinarians may observe:

• Improved muscle symmetry and tone on physical exam
• Increased stamina during walks or play
• Improved gait consistency and confidence, particularly in osteoarthritic patients
• Enhanced response to concurrent therapies (pain management, rehab, weight management)

This period is especially important for patients with chronic conditions such as osteoarthritis, CKD, or endocrine disease, where muscle loss can exacerbate morbidity and reduce quality of life. By supporting muscle mass, MYOS helps preserve functional independence—even when underlying disease remains present.

Clinical takeaway:
At six months, muscle support becomes clinically meaningful—patients move better, recover faster, and tolerate aging or disease with greater resilience.

Months 6–9: Supporting Longevity and Functional Independence

As patients approach nine months on MYOS, muscle health transitions from recovery to maintenance and long-term protection. This is a key stage for aging patients, where preserving what has been gained becomes just as important as building new muscle.

What veterinarians may observe:

• Slower progression of age-related mobility decline
• Improved balance and coordination in senior patients
• Reduced risk of falls or injury related to weakness
• Sustained muscle condition despite fluctuations in appetite or activity

For feline patients—particularly those with CKD or other chronic illnesses—this period may reflect improved ability to maintain body condition despite disease progression. In dogs, preserved muscle mass supports joint health by reducing biomechanical stress.

Clinical takeaway:
By nine months, MYOS becomes part of a longevity strategy—helping patients maintain independence, mobility, and quality of life as they age.

Months 9–12: A Year of Muscle Preservation and Healthier Aging

After a full year on MYOS, the benefits of consistent muscle support are often most apparent when compared to age-matched patients not receiving targeted muscle nutrition.

What veterinarians may observe:

• Improved long-term muscle condition scores relative to baseline
• Greater overall physical resilience in senior patients
• Delayed onset or progression of frailty
• Improved client perception of pet vitality and comfort

At this stage, MYOS is no longer a short-term intervention but a preventive tool—supporting healthy aging rather than reacting to decline. Maintaining muscle mass plays a central role in metabolic health, immune function, mobility, and survivability, making it a cornerstone of comprehensive wellness care.

Clinical takeaway:
Twelve months of MYOS use can redefine what “normal aging” looks like—shifting the trajectory toward strength, mobility, and longevity.

Looking Ahead: Making Muscle Health a Standard of Care

As we look toward 2026, proactive muscle support represents an opportunity to elevate patient care across life stages. Whether used in senior wellness plans, post-surgical recovery, chronic disease management, or early preventive care, MYOS offers veterinarians a clinically supported approach to preserving one of the most vital tissues in the body.

Muscle health is longevity.
And with MYOS, veterinarians can help ensure their patients enter the future stronger, more mobile, and better equipped to age well.